SecBot SecBot
8-K ·Filed Nov 9, 2026

WGS

GeneDx Holdings Corp.
BULLISH
Impact 6/10
Horizondays Processed7d 9h ago SEC0001628280-26-072172
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The EPS beat was driven by strong exome/genome volume growth and margin expansion. The slight trim to volume growth guidance for the full year bears watching, but Q4 guidance for $135M revenue and $12M adjusted net income implies continued sequential improvement.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$54.83
T+0 close · Nov 9, 2026 · via day close
Latest settled
+0.53%
T+1 · $55.12 · next T+5 in 5h
Vs SPY
−0.79%
α at T+1
Latest observation
−0.65%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $54.83entry
  2. T+1 · 6d ago +0.53%α −0.79% · $55.12
  3. T+4 · todayOpen
  4. T+5 · in 5h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GeneDx reported Q3 2026 revenue of $123.1M (+5% YoY) and adjusted EPS of $0.28, beating the $0.07 consensus. Exome and genome revenue grew 12% YoY to $110.4M on 25% volume growth. Full-year revenue guidance was reiterated at $475M-$490M, but exome and genome volume growth guidance was trimmed to at least 28% from at least 30%.

Key Financial Metrics

EPS (Adj.)
$0.28
est $0.07 · +300.0% · GAAP: $-0.41
Revenue
$123.1M
est $122.9M · +0.2% · +5.4% YoY
Rating
beat
Guidance
$475M-$490M
maintained
Gross Margin
69.9%

Key Facts

  • Q3 2026 total revenue $123.1M, +5% YoY
  • Exome and genome revenue $110.4M, +12% YoY
  • Exome and genome volume 32,134, +25% YoY
  • Adjusted diluted EPS $0.28 vs consensus $0.07
  • Adjusted net income $8.6M vs $0.4M in Q2 2026
  • Adjusted gross margin 72%, up from 70% in Q2 2026
  • Full-year 2026 revenue guidance reiterated at $475M-$490M
  • Full-year exome and genome volume growth guidance lowered to at least 28% from at least 30%
  • Cash and marketable securities $171.1M as of Sep 30, 2026

Financial Impact

Adjusted EPS of $0.28 versus consensus of $0.07, a 300% beat. Revenue of $123.1M slightly above consensus of $122.9M.

revenueepsgross marginvolume growth

Segment Breakdown

SegmentRevenueGrowth
Exome and genome$110.4M+12.0%
Other panels$9.7M-33.6%
Data and information$2.8M+86.7%
Software and interpretation services$200.0K-88.2%

Risk Factors

  • Full-year exome and genome volume growth guidance lowered to at least 28% from at least 30%
  • GAAP net loss of $12.3M in Q3 2026, though adjusted net income was positive
  • Operating cash flow negative $72M for the first nine months of 2026

Market Snapshot

Exchange
Nasdaq
Sector
Services-Health Services
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-072172
Exhibit: exhibit992q32026earnings.htm0001628280-26-072172
Document: wgs-20261109.htm0001628280-26-072172
Document: 0001628280-26-072172-index-headers.html0001628280-26-072172
Document: 0001628280-26-072172-index.html0001628280-26-072172
Document: 0001628280-26-072172.txt0001628280-26-072172
8-K Data (Synthetic)0001628280-26-072172

Track record

13 reports on WGS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +63.51% at T+60 after the May 20, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $52.37 Now $51.02 −2.58% settles Feb 11
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $54.83 Now $51.02 −6.95% settles Feb 8
  3. Nov 6, 202610d ago SC 13G Neutral 3/10 Entry $62.37 Now $51.02 −18.20% settles Feb 4
  4. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $97.83 Now $51.02 +47.85% settles Dec 15
  5. Sep 11, 20269w ago Insider Cluster Neutral 2/10 Entry $89.74 Now $51.02 −43.15% settles Dec 8
  6. Sep 1, 202610w ago 144 Neutral 2/10 Entry $86.72 Now $51.02 −41.17% settles Nov 27
  7. Jun 16, 202621w ago 8-K Neutral 3/10 Entry $60.60 to $83.96 Now $51.02 −15.81% ▲ +38.55% +37.55% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Bullish 4/10 Entry $59.92 to $85.87 Now $51.02 −14.85% ▲ +43.31% +40.04% vs SPY
  9. Jun 8, 202623w ago Insider Cluster Bullish 6/10 Entry $56.33 to $86.72 Now $51.02 −9.43% ▲ +53.95% +50.14% vs SPY
  10. May 20, 202625w ago Insider Cluster Bullish 6/10 Entry $47.33 to $77.39 Now $51.02 +7.80% ▲ +63.51% +59.21% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 7h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026